Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association Annual Scientific Meeting

Jun 21, 2010, 08:01 ET from Orexigen Therapeutics, Inc.

SAN DIEGO, June 21 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) and Empatic™ (zonisamide SR/bupropionSR) presentations taking place at the American Diabetes Association (ADA) 70th Scientific Sessions, June 25-29, 2010.  

ADA:  Orange County Convention Center (West Building), Orlando, FL.  

Friday, June 25:

Oral Presentation

Abstract: 56-OR

Presenter: Priscilla Hollander, M.D., Baylor Medical Center, Dallas, TX

Title: "COR-Diabetes: Naltrexone SR/Bupropion SR Combination Therapy Led to Significant and Sustained Weight Loss and Improved HbA1c in Overweight/Obese Subjects with Type 2 Diabetes"

Time: 5:45 p.m. EST

Location: Room 314

Oral Session: Obesity – Human

Sunday, June 27:  Poster Presentation

Poster Presentation

Abstract: 1851-P

Abstract: 1848-P

Presenter: Susan L. McElroy, M.D., Lindner Center of HOPE, Mason, OH

Presenter: Steven R. Smith, M.D., Pennington Biomedical Research Center, Baton Rouge, LA.

Title: "An Open-Label Study Evaluating the Naltrexone SR/BupropionSR Combination Therapy in Overweight or Obese Subjects with Major Depression"

Title: "Naltrexone SR/BupropionSR Combination Therapy Reduces Total and Visceral Adiposity in Overweight and Obese Subjects in the COR-I Study"

Time: 12:00 – 2:00 p.m. EST

Time: 12:00 – 2:00 p.m. EST

Location: Poster Hall

Location: Poster Hall

Category: 19-B Obesity – Human

Category: 19-B Obesity – Human

Guided Tour, Saturday, June 26th, 11:30a.m. - 12:30 p.m.

Guided Tour, Monday, June 28th, 1:00 - 2:00 p.m.

Poster Presentation

Published Abstract Only

Abstract: 1841-P

Abstract: 2633-PO

Presenter: Ken Fujioka, M.D., Scripps Clinic, Del Mar, CA

Presenter: Alok, K. Gupta, M.D., Pennington Biomedical Research Center, Baton Rouge, LA.

Title: "A Phase 2B, 24-week Study Evaluating the Efficacy and Safety of Two Doses of Zonisamide SR/BupropionSR Combination Therapy in Overweight and Obese Subjects"  

Title: "Improved Glycemic Control and Weight Loss with Naltrexone SR/BupropionSR Combination Therapy in Overweight/Obese Subjects with Type 2 Diabetes"

Time: 12:00 – 2:00 p.m. EST

Category: 19-B Obesity – Human

Location: Poster Hall

Guided Tour, Monday, June 28th, 1:00 - 2:00 p.m.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.

SOURCE Orexigen Therapeutics, Inc.



RELATED LINKS

http://www.orexigen.com